Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown

Biomaterials

Volumn 33, Issue 9, 2012, Pages 2754-2761

  Ryoo, Soo Ryoon ^c   Jang, Hongje ^c   Kim, Ki Sun ^b   Lee, Bokhui ^b   Kim, Kyung Bo ^b   Kim, Young Kwan ^c   Yeo, Woon Seok ^b   Lee, Younghoon ^c   Kim, Dong Eun ^b   Min, Dal Hee ^a  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

DNAzyme; Drug delivery; Magnetic nanoparticle; Virus

Indexed keywords

DELIVERY SYSTEMS; DNAZYME; DOWN-REGULATION; GENE ENCODES; GENE KNOCK DOWN; HELICASES; HEPATITIS C; HEPATITIS C VIRUS; HEPATOCYTES; HIGH POTENTIAL; IMMUNE RESPONSE; IN-VIVO; INORGANIC NANOPARTICLE; IRON OXIDE NANOPARTICLE; MAGNETIC NANOPARTICLES; NANOCOMPLEXES; NANOPARTICLE SYSTEMS; SEQUENCE-SPECIFIC MANNER; TARGET GENES; THERAPEUTIC APPLICATION; VIRUS REPLICATION;

DRUG DELIVERY; GENE EXPRESSION; GENE THERAPY; IRON OXIDES; NANOMAGNETICS; NANOPARTICLES; OLIGONUCLEOTIDES; VIRUSES;

GENE EXPRESSION REGULATION;

DNAZYME; HELICASE; IRON OXIDE; METAL NANOPARTICLE; MONTIRELIN; OLIGONUCLEOTIDE; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; GENE SILENCING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VIVO STUDY; LIVER CELL; PRIORITY JOURNAL; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DNA, CATALYTIC; FERRIC COMPOUNDS; GENE KNOCKDOWN TECHNIQUES; GENE TRANSFER TECHNIQUES; HEPACIVIRUS; HEPATOCYTES; HUMANS; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR SEQUENCE DATA; REPLICON; TISSUE DISTRIBUTION; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84855966009     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.12.015     Document Type: Article

References (43)

1. Li S.D., Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 2006, 13:1313-1319.
2. Bunnell B.A., Morgan R.A. Gene therapy for infectious diseases. Clin Microbiol Rev 1998, 11:42-56.
3. McCormick F. Cancer gene therapy: fringe or cutting edge?. Nat Rev Cancer 2001, 1:130-141.
4. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173-184.
5. Medarova Z., Pham W., Farrar C., Petkova V., Moore A. Invivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007, 13:372-377.
6. Askari F.K., McDonnell W.M. Antisense-oligonucleotide therapy. NEngl J Med 1996, 334:316-318.
7. McClorey G., Moulton H.M., Iversen P.L., Fletcher S., Wilton S.D. Antisense oligonucleotide-induced exon skipping restores dystrophin expression invitro in a canine model of DMD. Gene Ther 2006, 13:1373-1381.
8. Bai Y., Gong H., Li H., Vu G.P., Lu S., Liu F. Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice. Proc Natl Acad Sci USA 2011, 108:3222-3227.
9. Vaish N.K., Kore A.R., Eckstein F. Recent developments in the hammerhead ribozyme field. Nucleic Acids Res 1998, 26:5237-5242.
10. Dass C.R., Choong P.F., Khachigian L.M. DNAzyme technology and cancer therapy: cleave and let die. Mol Cancer Ther 2008, 7:243-251.
11. Appaiahgari M.B., Vrati S. DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain. Mol Ther 2007, 15:1593-1599.
12. Achenbach J.C., Chiuman W., Cruz R.P., Li Y. DNAzymes: from creation invitro to application invivo. Curr Pharm Biotechnol 2004, 5:321-336.
13. Dass C.R. Deoxyribozymes: cleaving a path to clinical trials. Trends Pharmacol Sci 2004, 25:395-397.
14. Santoro S.W., Joyce G.F. Ageneral purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997, 94:4262-4266.
15. Santoro S.W., Joyce G.F. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 1998, 37:13330-13342.
16. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
17. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
18. Reichard O., Norkrans G., Fryden A., Braconier J.H., Sonnerborg A., Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998, 351:83-87.
19. Bizollon T., Palazzo U., Ducerf C., Chevallier M., Elliott M., Baulieux J., et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997, 26:500-504.
20. Kowdley K.V. Hematologic side effects of interferon and ribavirin therapy. JClin Gastroenterol 2005, 39:S3-S8.
21. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N., et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37:443-451.
22. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A.M., Young S.K., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48:1769-1778.
23. Roy S., Gupta N., Subramanian N., Mondal T., Banerjea A.C., Das S. Sequence-specific cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication. JGen Virol 2008, 89:1579-1586.
24. Kumar D., Chaudhury I., Kar P., Das R.H. Site-specific cleavage of HCV genomic RNA and its cloned core and NS5B genes by DNAzyme. JGastroenterol Hepatol 2009, 24:872-878.
25. Lee B., Kim K.B., Oh S., Choi J.S., Park J.S., Min D.-H., et al. Suppression of hepatitis C virus genome replication in cells with RNA-cleaving DNA enzymes and short-hairpin RNA. Oligonucleotides 2010, 20:285-296.
26. Frick D.N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol 2007, 9:1-20.
27. Maga G., Gemma S., Fattorusso C., Locatelli G.A., Butini S., Persico M., et al. Specific targeting of hepatitis C virus NS3 RNA helicase. discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry 2005, 44:9637-9644.
28. Molday R.S., MacKenzie D. Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. JImmunol Methods 1982, 52:353-367.
29. Josephson L., Tung C.H., Moore A., Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 1999, 10:186-191.
30. Zhao M., Kircher M.F., Josephson L., Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 2002, 13:840-844.
31. Ngo T.T. Asimple spectrophotometric determination of solid supported amino groups. JBiochem Biophys Method 1986, 12:349-354.
32. Nelson A.R., Borland L., Allbritton N.L., Sims C.E. Myristoyl-based transport of peptides into living cells. Biochemistry 2007, 46:14771-14781.
33. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55:199-215.
34. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. JVirol 2001, 75:1252-1264.
35. Lohmann V., Hoffmann S., Herian U., Penin F., Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. JVirol 2003, 77:3007-3019.
36. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
37. Kariko K., Bhuyan P., Capodici J., Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. JImmunol 2004, 172:6545-6549.
38. Marques J.T., Williams B.R. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005, 23:1399-1405.
39. Kedmi R., Ben-Arie N., Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 2010, 31:6867-6875.
40. McAllister C.S., Samuel C.E. The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. JBiol Chem 2009, 284:1644-1651.
41. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002, 99:15661-15668.
42. Bukh J. Acritical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004, 39:1469-1475.
43. Zhu Q., Oei Y., Mendel D.B., Garrett E.N., Patawaran M.B., Hollenbach P.W., et al. Novel robust hepatitis C virus mouse efficacy model. Antimicrob Agents Chemother 2006, 50:3260-3268.